Thus, it is important to determine the status of GLS1 expression in HNSCC, and it is potentially beneficial to include a GLS1 inhibitor in treatment regimens for HNSCC patients with high GLS1 levels. This evidence concerns the gene GLS and head and neck squamous cell carcinoma.